Fresh analysis indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a leading medical journal points out that while obese individuals frequently drop a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these drugs should be informed of the potential of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery means a return to original mass within about a year and a half.
Comparing Approaches
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists note that people who shed pounds through dieting generally experience a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Doctors believe the way of the injections explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 levels far above than normal may cause the body to produce less of its own natural hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, considering the likelihood of relapse, the treatment is often life-long.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs report a powerful resurgence of appetite.
"I experienced a switch flipping and you become ravenous," described a patient.
The struggle is compounded if individuals have not developed sustainable lifestyle or habit modifications during treatment.
Growing Adoption
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while these medications are potent tools for shedding pounds, they are not a standalone solution and long-term success hinges on integrated behavioural management.